The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: Recent quality of life studies

Anti-Cancer Drugs

Volumn 9, Issue 9, 1998, Pages 783-790

  Allen, Mark ^a   Cunningham, David ^a   Schmitt, Claude ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ARCOS Hlth Econ Qual of Life Res   (France)

Author keywords

Colorectal carcinoma; Endpoint; Quality of life; Stabilization

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN;

ARTICLE; BUDGET; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; FRANCE; GREAT BRITAIN; HEALTH STATUS; HUMANS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 0031730842     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199810000-00007     Document Type: Article

References (17)

1. OPCS. 1989 Cancer statistics: registrations, England and Wales. OPCS 1994; 26-7.
2. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th edn. Philadelphia: Lippincott 1993: 929-77.
3. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A: 2077-9.
4. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5.
5. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 1992; 10: 904-11.
6. Hilgenfeld RU, Streit M, Theil E, Kreuser ED. Current treatment modalities in advanced colorectal carcinoma. Recent Results Cancer Res 1996; 142: 353-80.
7. Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation [Review]. Eur J Cancer 1996; 32A (suppl 3): S1-8.
8. Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996; 32A (suppl 3): S13-7.
9. Cunningham D et al. Open-label multicentre phase II study to confirm efficacy and safety of irinotecan-HCl (CPT-11) in metastatic 5-FU resistant colorectal cancer (CRC). Br J Cancer 1996; 74 (suppl XXVIII): abstr 034.
10. Massey A. New innovative treatment in metastatic colorectal cancer. Int J Palliative Nursing 1996; 3: 171-4.
11. Data on file. Rhône-Poulenc Rorer.
12. Borset JF, de Gramont A, et al. Randomised phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose leucovorin in metastatic colorectal cancer. Eur J Cancer 1995; 31A (suppl 5).
13. Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Palliative Nursing 1997; 3: 276-80.
14. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press 1987: 126-8.
15. Wiseman LR, Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606-23.
16. Glimelius B, et al. for the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
17. Jager W, Bernard H, Knuth A. Palliative treatment for advanced gastrointestinal cancer: is response a suitable endpoint? Cancer Treat Rev 1996; 22 (suppl A): 113-5.